Centenary of the 1918 influenza pandemic: preparing for the next one
2018 WORLD INFLUENZA CONFERENCE
Date: 7th – 10th September 2018
Location: Beijing Conference Center 88 Laiguangying West Road, Chaoyang District, Beijing, China
This year marks the centenary of the first recorded influenza pandemic with devastating mortality globally in 1918. We had also experienced three subsequent influenza pandemics with the latest in 2009. Many lessons were learnt and influenza pandemic preparedness plans were revised and improved. However, many challenges remain and the 2018 World Influenza Conference was aimed at addressing the question on whether we are prepared for the next one.
The 2018 World Influenza Conference was hosted by the Chinese Association of Preventive Medicine (CPMA), China Center for Disease Control and Prevention (China CDC), Chinese Academy of Medical Sciences (CAMS), and the Asia-Pacific Alliance for the Control of Influenza (APACI). The conference was organized in collaboration with the European Scientific Working group on Influenza (ESWI), the National Adult and Influenza Immunization Summit (NAIIS) and the International Society for Influenza and other Respiratory Virus Diseases (isirv).
ZHANG Wenqing, Global Influenza Program, WHO. Pandemic Influenza Preparedness – a WHO Perspective
George Fu GAO, Director-General, China CDC. Overview of pandemic and pandemic preparedness in China
Rick BRIGHT, Director, Biomedical Advanced Research and Development Authority (USA). A multifaceted approach in the development of treatment and prevention of pandemic influenza: successes and challenges
WANG Chen, President, Chinese Academy of Medical Sciences (China). From SARS to influenza: the construction and improvement of China’s clinical diagnosis and treatment system
Plenary Lectures 1 – global impact of influenza pandemics
Arnold MONTO (USA). Impact and lessons learned from influenza pandemics in the last 100 years
Ab OSTERHAUS (Germany). Pandemic influenza viruses and avian viruses
Ruben DONIS (USA). Pathogenic characteristics of pandemic influenza viruses
PresentationMark JIT (UK). Economic impact of seasonal and pandemic influenza
Plenary Lectures 2 – pandemic preparedness plans and policy
ZHOU Weigong (WHO). Pandemic Influenza Preparedness – WHO’s efforts in countries support
PresentationAnne HUVOS (WHO). Access and benefit sharing: the objectives and progress of the WHO Pandemic Influenza Preparedness (PIP) framework
PresentationMassimo CIOTTI (ECDC). Influenza Pandemic Preparedness: Europe
PresentationVernon LEE (Singapore). Influenza pandemic preparedness: perspectives from Singapore and Asia
Norio SUGAYA (Japan). Influenza antivirals usage in pandemic situation
PresentationPlenary Lectures 3 – elements of influenza pandemic readiness
SHU Yuelong (China). Improving the global surveillance network for novel influenza viruses with pandemic potentials
Presentation
Hui-Ling YEN (China). Integration of animal influenza surveillance into influenza pandemic planning
Florian KRAMMER (USA). Global development of universal pandemic influenza vaccines
Marie MAZUR (USA). Use of adjuvant in influenza vaccines
Gary GROHMANN (Australia). Regulatory issues relating to rapid approval and distribution of pandemic influenza vaccines
CAO Bin (China). Progress of antiviral agents
JIANG Chengyu (China). Repurposing drugs to protect mice from H5N1 virus induced acute lung injury
Plenary Lectures 4 – elements of influenza pandemic response
ZHANG Wenqing (WHO). Vaccine response at the start of a pandemic – issues surrounding “switch” from seasonal to pandemic vaccine production
Woo Joo KIM (S. Korea). Extending lessons learned during the MERS outbreak to influenza pandemic response in South Korea
LI Qun (China). Review of the response to the 2009 H1N1 pandemic in China
Beverly TAYLOR (IFPMA). Global pandemic preparedness and response: manufacturers perspectives
David HUI (China). Extending clinical management of SARI during interpandemic time to address severe influenza in pandemics
PresentationLitjen TAN (USA). Advocacy and communication strategies to promote universal influenza vaccination in the USA: achievements and challenges
PresentationPlenary Lectures 5 – integrating seasonal influenza intervention strategies as part of pandemic planning
Joe BRESEE (USA). Seasonal influenza vaccine usage and pandemic preparedness planning
PresentationGeorge KASSIANOS (UK). Strategies to increase seasonal influenza vaccine usage: UK experience
SHEN Kunling (China). Progress of clinical characters and treatments in children with influenza
PresentationBen COWLING (China). Application and efficacy of interventions for influenza transmission in seasonal epidemics and pandemics
PresentationBreak-out session 1: ensuring the adequacy of countries’ pandemic preparedness plans
Hitoshi OSHITANI (Japan). Pandemic preparedness planning in Asia: successes and gaps
Vincent PANG (Singapore). Strategies for evidence-based pandemic preparedness planning
PresentationDavid SMITH (Australia). Influenza Pandemic Planning: Australia and New Zealand
PresentationHemant Chandra OJHA (Nepal). Influenza Pandemic Planning: Nepal
William AMPOFO (Ghana). Influenza Pandemic Preparedness: Africa
PresentationZHOU Lei (China). Overview of H7N9 outbreak and response
PresentationHUANG Baoxu (China). Surveillance and control of avian influenza among poultry in China
Break-out session 2: pandemic influenza surveillance, laboratory diagnosis and early warning systems
WANG Dayan. Development of Influenza Surveillance Network in China
PresentationLI Chengjun (China). Evolution and control of H7N9 influenza viruses H7N9
SHU Yuelong (China). Lessons learned from H7N9 outbreak response for next pandemic preparedness and response
PresentationZHANG Yanping (China). Surveillance of novel influenza virus in China
TIAN Huaiyu (China). Geneflow networks and spread of avian influenza virus
DU Xiangjun (China). Computational systems biology of influenza: a short story
Break-out session 3: effectiveness of public health interventions for influenza in pandemics
ZHOU Weigong (WHO). Overview on guidance for non-pharmaceutical interventions
PresentationYANG Lin (China). Effectiveness of non-pharmaceutical interventions in controlling influenza in hospital settings
Ben COWLING (China). Evidence base and knowledge gaps on non-pharmaceutical interventions
PresentationWU Xiaoxing (China). Research on Influenza vaccine technology and the development of new influenza vaccine
YANG Yonghong (China). Protecting Chinese children from invasive pneumococcal diseases
Break-out session 4: implementation of seasonal and pandemic influenza vaccination
FENG Luzhao (China). Recommendation and policy of influenza vaccination in China
PresentationYU Hongjie (China). Cell culture-based recombinant influenza vaccines
Emanuele MONTOMOLI (Italy). Correlates of protection in influenza vaccine immunology
PresentationParvaiz KOUL (India). Implementation of influenza vaccination in India: accomplishments and challenges
PresentationBurmaa ALEXANDER (Mongolia). Experience with influenza vaccine introduction in Mongolia
PresentationAnonh XEUATVONGSA (Lao). Lessons in sustainability of influenza vaccination programs – the Lao PDR experience
Pyanit THARMAPHORPILAS (Thailand). Thailand’s experience with expanding influenza vaccination
Yao Hangping (China). Novel strategies for prevention of influenza-universal influenza vaccine / prophylactic Immunomodulator
Break-out session 5: implementation of seasonal and pandemic antiviral treatment
Arnold MONTO (US). How should oseltamivir be used?
PresentationWENG Heng (China). Clinical evidence of NAIs on prevention and treatment of influenza
LU Hongzhou (China). Influenza standardized treatment
GUO Qiang (China). The therapeutic value of favipiravir on influenza and other viruses
PresentationDavid HUI (China). The role of adjuvant immunomodulatory agents for the treatment of severe influenza
PresentationCAO Bin (China). The clinical trial progress of baloxavir marboxil
JIA Zhenhua(China). Clinical value of traditional Chinese Medicine in the prevention and treatment of influenza
Break-out session 6: influenza virology and basic research to address pandemic readiness
Jennifer GORDAN & Alison AUGUSTINE (USA). NIAID’s Priorities to support broadly protective influenza vaccines
PresentationXU Jianqing (China). Protective immune responses during H7N9 infection
Florian KRAMMER (USA). Universal influenza vaccine development based on the conserved stalk domain of the influenza virus hemagglutinin
PresentationLIU Wenjun (China). Phosphyorylation Controls the Replication of influenza Virus
WANG Jianwei (China). Host factors involved in influenza virus infection: new targets for intervention
DENG Tao (China). Further characterizing the non-coding regions of influenza viruses
XU Ke (China). Histone demethylase LSD1 restricts influenza A virus infection by erasing IFITM3-K88 monomethylation
